Travoprost/Brinzolamide Fixed Combination Versus Travatan and Versus AZOPT

Exclusion Criteria

• •Related to disease condition being investigated (OAG or OHT) in either eye
• •Severe central visual field loss
• •Angle shaffer grade \< 2
• •C/D ratio \>0.8(horizontal or vertical measurement)
• •Related to ocular patient history or current ocular condition in either eye
• •BSCVA worse than 55 ETDRS letters read (equivalent to approximately 20/80 Snellen or 0.25 decimal)
• •Ocular infection or inflammation or laser surgery within the last 3 months
• •Intraocular surgery or trauma with the last 6 months
• •Any abnormality preventing reliable applanation tonometry
• •History or chronic, recurrently or current severe inflammatory disease
• •History of or current clinically significant or progressive retinal disease
• •History of or current ocular pathology(including severe dry eye) that would affect the conduct of the study
• •Related to systemic or ocular medication in either eye
• •Allergy/hypersensitivity to study medications
• •Unable to discontinue glucocorticoid at least 4 weeks prior to the study or unable to remain off these medications during the study period
• •Use of oral CAIs during the study
• •Recent use (\<4 weeks prior to the study) of Aspirin (\>1 gram)
• •Less than 30 days stable dosing regimen of medications used on a chronic basis that may affect IOP
• •Therapy with another investigational agent within 30 days prior to the Screening Visit